Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

e patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

Clinical Trials - Recently Filed Application

In the first quarter of 2008, the NCI filed a protocol with the U.S. Food and Drug Administration for a Phase I/II clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R). The trial, which is being carried out at The Ohio State University Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian, peritoneal or fallopian tube cancers. These cancer indications were selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill ovarian cancer cells.

Pre-Clinical Trial and Collaborative Program

In the first quarter of 2008, we reported that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled "Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus" appeared online in the January 1, 2008 issue of Clinical Cancer Research.

The purpose of the research study was to investigate whether it was possible to use cyclophosphamide, an immune modulator, to enhance the delivery and replication of the reovirus when delivered intravenously. After testing various doses and dosing regimens of reovirus and cyclophosphamide in mice, a metronomic dosing regimen was developed that resulted in increased survival, high levels of reovirus recovered fr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/s3s3t8/personalized ) ... report "Personalized Medicine - Scientific and Commercial ... The aim of personalized medicine or individualized ... the right patient and, in some cases, even ... according to his/her genotype. This report describes the ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... viral vectors, nonviral vectors and cell therapy with ... method of drug delivery and various routes of ...
(Date:3/3/2015)... PHILADELPHIA , March 3, 2015 ... agencies with tools for implementing competency-based training to comply ... DirectCourse is offering a new crosswalk ... Services (HCBS) implement competency-based training for direct service workers ... Medicare & Medicaid Services (CMS) regulations. CMS ...
(Date:3/3/2015)... 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... focus on protecting the microbiome, announced today that Jeffrey ... the 27th Annual ROTH Conference being held on March 8-11, ... in Dana Point, CA. Mr. Riley ... 1:00 p.m. (Pacific Time). A live webcast of ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Calif., Feb. 11 MannKind Corporation (Nasdaq: ... quarter financial results on Tuesday, February 17, 2009.Management of ... the fourth quarter financial results, clinical progress and other ... 17, 2009. Presenting from the Company will be its ...
... in biological research and drug discovery are bracing for ... LLC ( www.gene2drug.com ), the premier research and advisory ... data from the company,s newest report Prospering ... In this report, we set out to understand ...
... QUEBEC, Feb. 11 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., ... patent application for the detection and treatment of a ... death in epileptic patients during seizure. , Victhom has ... and device aimed at preventing sudden unexpected death in ...
Cached Biology Technology:MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009 2Life Science Labs Reacting to the Economic Crisis 2Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP) 2Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP) 3
(Date:2/18/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. , Cowen and Company ... March 3, 2015 at 11.20 a.m. Eastern Time , ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... for these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE SERVICES ... NXT-ID,s position in the emerging "Internet of Things" by ... multiple devices to collaborate with one another to improve ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Ind. - An animal study at Purdue University has shown ... help the body absorb helpful compounds and also demonstrates the ... animals needed for these types of studies. Mario Ferruzzi, ... model with human intestinal cells to show that adding ascorbic ...
... Haven, Conn.The large group of segmented worms known as annelids, ... years ago and can be found in every corner of ... animal groups on the planet, scientists have struggled to understand ... to each other in terms of their evolutionary history. Now ...
... a plant used a century ago during the great Spanish ... in killing the H1N1 swine flu virus that now threatens ... cooked, but when raw it has sap so foul-smelling that ... report is scheduled for the Sept. 25 issue of ACS, ...
Cached Biology News:Model backs green tea and lemon claim, lessens need to test animals 2Scientists use microRNAs to track evolutionary history for first time 2